Dr. Hoos Describes Ipilimumab and Future Immunotherapies

Video

Dr. Axel Hoos medical lead from Bristol-Myers Squibb Describes Ipilimumab and Future Immunotherapies

Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb discusses ipilimumab (Yervoy) and how it is a first-in-class agent that enhances activation of T cells. He elaborates that Bristol-Myers Squibb plans to build upon this success with their new drug the anti-PD-1 agent MDX-1106.

Related Videos
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD
Elias Jabbour, MD
Shruti Tiwari, MD
Jeffrey P. Townsend, PhD
Marina Baretti, MD
George R. Simon, MD, FACP, FCCP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
Related Content
Hesham Abdullah, MD

Dostarlimab/Chemo Receives FDA Priority Review for Expanded Indication in Endometrial Cancer

April 24th 2024
Article
Jeffrey S. Weber, MD, PhD

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

November 6th 2023
Podcast
Rodabe N. Amaria, MD

OBX-115 With Acetazolamide Induces Safe and Durable Antitumor Responses in Advanced Melanoma

April 23rd 2024
Article
Nikhil I. Khushalani, MD; Martin F. Dietrich, MD, PhD; Jason J. Luke, MD, FACP; Vishal A. Patel, MD, FAAD, FACMS

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

March 6th 2023
Podcast
Professor Lindy Durrant

SCIB1 Plus Nivolumab/Ipilimumab Generates ORR of 85% in Advanced Unresectable Melanoma

April 22nd 2024
Article
FDA

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC

April 18th 2024
Article